Medical/Pharmaceuticals

Preserving fertility and optimising care for the one in seven women suffering from endometriosis

SINGAPORE, May 1, 2025 /PRNewswire/ -- Fertility specialists in the Asia Pacific region are bringing to fruition new standards of care for women and girls suffering from endometriosis and to help preserve the fertility of those with the debilitating condition. They have finalised a rigorous co...

2025-05-01 08:29 2567

S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial

SEOUL, South Korea, May 1, 2025 /PRNewswire/ -- S&E bio Co., Ltd. , a biotechnology company specializing in exosomal microRNA-based therapies, has received approval from Korea's Ministry of Food and Drug Safety (MFDS) to initiate a Phase 1b clinical trial of its investiga...

2025-05-01 08:00 2766

Natus announces integration of InVisus Pro NMUS into Natus Elite software

MIDDLETON, Wis., May 1, 2025 /PRNewswire/ -- Natus Medical Incorporated has announced its InVisus Pro Neuromuscular Ultrasound system can now be seamlessly integrated with all Natus EMG systems via Natus Elite Software, providing users of the portable, stand-alone neuromuscular ultrasound with th...

2025-05-01 03:15 2763

ZEISS unveils AI-powered Research Data Platform; collaboration with Boehringer Ingelheim champions the future of personalized eye care

Showcasing the future of ophthalmic research at ARVO 2025: * ZEISS Research Data Platform launch - a cloud-based, AI-driven technology solution designed to accelerate discoveries, integrating research and clinical data, and simplifying research workflows. * ZEISS's collaboration with Boehring...

2025-04-30 21:00 2379

Gedeon Richter: Medical Treatment of Endometriosis with a progressive approach

PRAGUE and BUDAPEST, Hungary, April 30, 2025 /PRNewswire/ -- Modern medical treatment options for endometriosis were among the main topics at the SEUD Congress  (Society of Endometriosis and Uterine Disorders) held in Prague between 24-26 April, where a highly successful sympos...

2025-04-30 19:00 2185

AXA Enhances GBA Medical Concierge Service Network

Launches First-Ever Northbound and Southbound Cancer Care Available to Both Individual and Group Customers HONG KONG, April 30, 2025 /PRNewswire/ -- AXA Hong Kong and Macau ("AXA") today announced a comprehensive upgrade to its GBA Medical Concierge Service Network. This enhancement includes an ...

2025-04-30 13:48 2626

Alphamab Oncology Presented Preclinical Data on Two Novel Bispecific ADCs at the 2025 AACR Annual Meeting

SUZHOU, China, April 30, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the preclinical data on two novel bispecific antibody-drug conjugates (ADCs) JSKN021 and JSKN022 were presented as posters at the 2025 American Association for Cancer Research (AACR) Annual Meetin...

2025-04-30 10:35 2773

Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies

SAN FRANCISCO and SUZHOU, China, April 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...

2025-04-30 08:00 2847

Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Hong Kong

SHANGHAI, April 30, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the Department of Health of the...

2025-04-30 07:45 2639

Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar

* Partnership covers North America, Europe, Japan, and Australia to accelerate global access of HLX13 in immuno-oncology combinations * Henlius to receive $31 million upfront, and up to $270 million in milestones SHANGHAI, April 29, 2025 /PRNewswire/ -- On April 29, 2025, Shanghai Henlius Biot...

2025-04-29 23:39 3119

Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar

* Partnership covers North America, Europe, Japan, and Australia to accelerate global access of HLX13 in immuno-oncology combinations * Henlius to receive $31 million upfront, and up to $270 million in milestones SHANGHAI, April 29, 2025 /PRNewswire/ -- On April 29, 2025, Shanghai Henlius Biot...

2025-04-29 23:38 2662

PHASE Scientific Earns Prestigious Recognition at 2025 ASCCP Scientific Meeting for Innovation in Urine-Based HPV Screening

SAN DIEGO, April 29, 2025 /PRNewswire/ -- PHASE Scientific (PHASE) proudly announced a major milestone this week with its inaugural participation and award-winning presentation at the 2025 American Society for Colposcopy and Cervical Pathology (ASCCP) Annual Scientific Meeting — one of the foremo...

2025-04-29 22:00 2448

Metabolon Launches Microbiome Research Solution Combining New Microbiome Panel, Metagenomics Sequencing, and Multiomics Bioinformatics Tools

The combination of metagenomics and metabolomics data, integrated within an intuitive bioinformatics platform, enables deeper microbiome insights than possible with either approach individually MORRISVILLE, N.C., April 29, 2025 /PRNewswire/ -- Metabolon, Inc., the global leader in providing met...

2025-04-29 21:00 1720

Continuity Biosciences Invests in PinPrint, Inc., Expanding into Aesthetic and Cosmetic Drug Delivery

BRADENTON, Fla., April 29, 2025 /PRNewswire/ -- Continuity Biosciences, LLC has made a strategic investment in PinPrint, Inc., a pioneering company in high-resolution 3D-printed microneedle technology. The investment expands Continuity's footprint beyond therapeutic delivery into aesthetic and co...

2025-04-29 20:00 2242

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

European Commission converts conditional approval of FILSPARI (sparsentan)  into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive recommendation from Committee for Medicinal Products for Human Use (CHMP) from February 2025 EU approval is b...

2025-04-29 14:00 2287

Amorepacific Research Confirms Potential of Microalgal-Derived PDRNs in Skin Regeneration and Wound Healing

New findings suggest 'BluePDRN™' offers a sustainable, scalable alternative to traditional animal-derived PDRNs SEOUL, South Korea, April 29, 2025 /PRNewswire/ -- Amorepacific revealed research findings confirming the skin-regenerative effects of polydeoxyribonucleotides (PDRNs) extracted from ...

2025-04-29 09:00 2807

AI Evolution and Life Sciences: Embracing New Frontiers at Dalton Venture CEO Summit 2025

 HONG KONG, April 29, 2025 /PRNewswire/ -- Dalton Venture CEO Summit 2025 , jointly hosted by Dalton Venture and Hong Kong Science and Technology Parks Corporation (HKSTP), successfully concluded at Hong Kong Science Park. The summit brought together over 100 distinguished guests, including gover...

2025-04-29 07:00 2916

Telix's Illuccix PSMA-PET Imaging Agent Approved in France

New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent MELBOURNE, Australia, April 29, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent, Illucci...

2025-04-29 06:30 2324

SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR

BOSTON and ROLLE, Switzerland, April 29, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the...

2025-04-29 01:37 2742

KOLON TISSUEGENE HIGHLIGHTS LONG-TERM SAFETY DATA AND POTENTIAL U.S. FDA PATHWAY FOR TG-C AT OARSI WORLD CONGRESS

* THE WORLD'S MOST PRESTIGIOUS OSTEOARTHRITIS SOCIETY (OARSI) HELD FOR THE FIRST TIME IN KOREA  * LONG-TERM SAFETY DATA FROM OVER 1 5  YEARS SUPPORT THE SAFETY PROFILE OF TG-C, WITH PRELIMINARY SIGNS OF POTENTIAL EFFICACY BENEFITS ROCKVILLE, Md., April 28, 2025 /PRNewswire/ -- Kolon TissueGen...

2025-04-28 21:16 3006
1 ... 55565758596061 ... 395